Syngeneic models

Circle Oncodesign Services

 Syngeneic Models for Drug-Host Immune System Interactions Study


Treatments targeting immune cells such as immune checkpoint modulators, bispecific antibodies or adoptive T cell transfer have now demonstrated their clinical efficacy and some of these therapies have already been approved. However, preclinical development of these therapies requires models adapted to each target and class of therapeutics. To address these needs, Oncodesign Services provides the option to use syngeneic mouse models.

Syngeneic model systems remain one of the best options to analyze physiologically relevant interactions between tumor and immune cells. Indeed, in syngeneic models, animals are grafted with tumor cells from an animal of the same lineage. The main advantage of these models is the use of immunocompetent mice, thus allowing the study of the complex relationships between cancer and the immune system and the evaluation of immunomodulatory therapies.


Different kind of tumor models

Oncodesign Services provides a large bank of syngeneic tumor models, including breast cancer, melanoma, bladder cancer, etc .


Readouts in mouse syngeneic models

Tumor volume


Functional assays


Cytokine profiles

Examples of syngeneic mouse tumor models available at Oncodesign Services

(contact us for complete list)

Name Organ Histological Type Host rodent species
4T1 Breast Carcinoma transitional Balb/c Mouse
AY27 Bladder Carcinoma F344 Ficher Rat
C6 Brain Glioma Nude Rat
C6 Brain Glioma Wistar Rat
CT26 Colon Carcinoma Balb/c Mouse
EMT6 Breast Mammary Carcinoma Balb/c Mouse
GS-9L Brain Gliosarcoma F344 Ficher Rat
GV1A1 Brain Glioma BDIX Rat
Hepa1-6 Liver Hepatocarcinoma C57BI/6 Mouse
MBT-2 Bladder Carcinoma C3H Mouse
MBT-II Bladder Tumor Wistar Rat
NCTC 2472 Bone Sarcoma C3H Mouse
R3327H Prostate Adenocarcinoma Copenhagen Rat
Renca Kidney Carcinoma Balb/c Mouse




Explore our tumor bank

Case study: MC38 colon tumor model


Subcutaneous MC38 model -immunotherapy

Syngeneic mice were subcutaneously injected with MC38 murine tumor fragments on Day 0. The mice were randomized based on their tumor volumes on Day 11 and treated intraperitoneally with 10mg/kg/inj of mAb against CTLA-4 (clone9H10, TWx2), PD-1 (cloneRMP1-14, TWx2), PD-L1 (clone10F.9G2, TWx2) or left untreated.


Get in touch